John C. Byrd
Division of Hematology and Oncology
Comprehensive Cancer Center
The Ohio State University
Columbus 43210-1240
USA
Name/email consistency: high
- Treatment of relapsed chronic lymphocytic leukemia: old and new therapies. Byrd, J.C., Lin, T.S., Grever, M.R. Semin. Oncol. (2006)
- A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Byrd, J.C., Marcucci, G., Parthun, M.R., Xiao, J.J., Klisovic, R.B., Moran, M., Lin, T.S., Liu, S., Sklenar, A.R., Davis, M.E., Lucas, D.M., Fischer, B., Shank, R., Tejaswi, S.L., Binkley, P., Wright, J., Chan, K.K., Grever, M.R. Blood (2005)
- Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Byrd, J.C., Peterson, B.L., Gabrilove, J., Odenike, O.M., Grever, M.R., Rai, K., Larson, R.A. Clin. Cancer Res. (2005)
- Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. Byrd, J.C., Ruppert, A.S., Mrózek, K., Carroll, A.J., Edwards, C.G., Arthur, D.C., Pettenati, M.J., Stamberg, J., Koduru, P.R., Moore, J.O., Mayer, R.J., Davey, F.R., Larson, R.A., Bloomfield, C.D. J. Clin. Oncol. (2004)
- Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Byrd, J.C., Peterson, B.L., Morrison, V.A., Park, K., Jacobson, R., Hoke, E., Vardiman, J.W., Rai, K., Schiffer, C.A., Larson, R.A. Blood (2003)
- Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Byrd, J.C., Smith, L., Hackbarth, M.L., Flinn, I.W., Young, D., Proffitt, J.H., Heerema, N.A. Cancer Res. (2003)
- KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis. Byrd, J.C., Lucas, D.M., Mone, A.P., Kitner, J.B., Drabick, J.J., Grever, M.R. Blood (2003)
- Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. Bannerji, R., Kitada, S., Flinn, I.W., Pearson, M., Young, D., Reed, J.C., Byrd, J.C. J. Clin. Oncol. (2003)
- Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Byrd, J.C., Mrózek, K., Dodge, R.K., Carroll, A.J., Edwards, C.G., Arthur, D.C., Pettenati, M.J., Patil, S.R., Rao, K.W., Watson, M.S., Koduru, P.R., Moore, J.O., Stone, R.M., Mayer, R.J., Feldman, E.J., Davey, F.R., Schiffer, C.A., Larson, R.A., Bloomfield, C.D. Blood (2002)
- UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism. Byrd, J.C., Shinn, C., Willis, C.R., Flinn, I.W., Lehman, T., Sausville, E., Lucas, D., Grever, M.R. Exp. Hematol. (2001)